1. Scrip
  2. >>Business

India's Mankind Licenses Entresto From Novartis, Acquires Panacea’s Brands

$1Bn Revenue Forecast For FY22

 
• By Vibha Ravi

Mankind Pharma has licensed Novartis’ heart failure therapy Entresto in India, executive chairman Ramesh Juneja tells Scrip. The privately-owned company has also acquired the generics business of Panacea in India and Nepal for over $255m.

Handshake Showing Concept Of A Deal
Mankind Pharma Strikes Two Deals • Source: Alamy

Mankind Pharma Ltd. has entered into an agreement with Novartis AG to license the heart failure therapy Entresto (sacubitril/valsartan) that the latter sells in India as Vymada.

“We will market and distribute the product under our brand Neptaz and Novartis will manufacture it,” Ramesh Juneja, founder and executive chairman of the privately-owned Indian

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.